arrow
P

Paola Guglielmelli

azienda ospedaliero-universitaria careggi
H指数:77
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience

克洛拉拉滨联合中剂量阿糖胞苷在维奈克拉耐药后的复发/难治性急性髓系白血病中的应用:一项回顾性单中心经验

2026-11-040
OAAI
Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera

低剂量罗肽干扰素在低风险真性红细胞增多症中实现<i>JAK2V617F</i>分子反应的长期深化

2026-10-260
PRE
Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

FLT3-ITD突变白血病干细胞的表征:功能与临床见解

2026-09-280
OAAI
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities

真性红细胞增多症和原发性血小板增多症中的自身免疫和炎症性疾病:对疾病结局和合并症的影响

2026-04-170
OAAI
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications

NPM1突变AML中APL样亚群:一种与早期血管并发症相关的独特免疫表型

2026-04-160
OA
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia

基于Venetoclax的联合方案在复发/难治或MRD阳性NPM1突变急性髓系白血病中的临床经验

2026-04-010
OAAI
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images

人工智能利用数字化骨髓活检图像区分伴血栓形成性血小板增多症的早期原发性骨髓纤维化与原发性血小板增多症

Leukemia
IF13.4
2026-02-200
OAAI
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm

一种新型、Ruxolitinib敏感的CCDC6::JAK2融合基因,存在于一位患有非典型、JAK2未突变、类真性红细胞增多症、骨髓增殖性肿瘤的患者中

2025-12-030
OAAI
Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model

联合MEK和JAK抑制可降低骨髓纤维化小鼠模型中的骨桥蛋白血浆水平及骨髓纤维化程度。

2025-11-150
OAAI
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40

全基因组分析确定了MPN亚型的遗传决定因素,并识别了CDH22/CD40位点的性别特异性关联。

Blood
IF23.1
2025-10-030
PRE
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries

尽管起始剂量有所减少,接受鲁索利替尼治疗的骨髓纤维化患者的治疗持续性和总生存期并未受到COVID-19大流行的影响:意大利药品管理局登记数据分析

2025-09-200
OA
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients

三重A加(AAA+)生存预测模型用于原发性血小板增多症:涉及7308例患者的分析

2025-09-030
OAAI
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera

中性粒细胞与淋巴细胞比值作为JAK2V617F抑制和事件-free生存的替代指标在真性红细胞增多症中的应用

2025-08-060
OAAI
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature plasmacytoid dendritic cell proliferation (MPDCP): the same cell of origin from a clonal haematopoiesis of indeterminate potential (CHIP)?

原始幼稚浆树突状细胞肿瘤(Blastic plasmacytoid dendritic cell neoplasm, BPDCN)和成熟浆树突状细胞增生(mature plasmacytoid dendritic cell proliferation, MPDCP):是否源自具有不确定潜能的克隆性造血(clonal haematopoiesis of indeterminate potential, CHIP)的同一细胞?

2025-07-290
PRE